Post-earnings recap
Reported
Thu, Feb 24, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Madrigal Pharmaceuticals reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising 7.13%. The company did not disclose revenue figures, but management's optimistic tone suggests they are focused on future growth and pipeline advancements. Investors may view the EPS beat as a sign of progress.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.78 | N/A | +3.52% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results despite not providing revenue figures. They emphasized their commitment to pipeline development.
We are pleased with our progress and the results we achieved this quarter.
Our focus remains on advancing our pipeline and preparing for future opportunities.